Abstract:Critical sized cartilage defects heal poorly and MSC-based therapies holds promise functional cartilage regeneration either used alone or in combination with growth factors. However, Recombinant protein growth factors were proven to have minimal benefits while to have adverse side effects and high cost. Nonviral mRNA delivery provides a promising, alternative approach to delivering therapeutic proteins within defect lesion for an extended period of time. Despite successful therapeutic outcome in bone and other vascularized tissues, the therapeutic application of mRNA in poorly vascularized tissues such as cartilage is still facing many challenges and rarely studied. We report here using chemically modified messenger RNA encoding TGF-β3(TGF-β3 cmRNA) to enhance the therapeutic efficacy of BMSCs to efficient repair of cartilage defect. Local administration of TGF-β3 cmRNA enhanced BMSCs therapy restored critical-sized cartilage defects in situ in a rat model within 6 weeks with structural and molecular markers similar to its nature counterparts. In addition, the development of osteoarthritis caused by cartilage damage was prevented by this mRNA-enhanced BMSCs therapy evidenced by minimal late-stage OA pharmacological presentations. This novel mRNA enhanced-MSC technology extend the development of new therapeutic approaches for treating functional cartilage repair. ### Competing Interest Statement YY received the research funding from:National Nature Science Foundation of China (82002355), Shenzhen Institute of Synthetic Biology Scientific Research Program (Grant No. DWKF20190010, JCHZ20200005), FC received the research funding from: the Shenzhen Institutes of Advanced Technology Innovation Program for Excellent Young Researchers (Y9G075), GeneHeal Medicine-SIAT mRNA Regenerative Medicine Laboratory (E1Z124) . LZ received the research funding from: the National Natural Science Foundation of China [81660364, 81760343], Jiangxi Provincial Department of Education Research Program Major Project (171352), Science and Technology Planning Project of Jiangxi Health Commission (20191025, 202130131). XZ received the research funding National Nature Science Foundation of China (32071341). GW, JH, FY are employee at Gene Heal Medicine, a privately owned company developing mRNA therapeutics.All others have no potential conflict of interest.

Chitosan-gelatin Hydrogel/plga Scaffold with Dual-Delivery of TGF-β1 and BMP-2 for Osteochondral Defect Repair

Cartilage-Targeting Mrna-Lipid Nanoparticles Rescue Perifocal Apoptotic Chondrocytes for Integrative Cartilage Repair

Incorporation of Osteogenic and Angiogenic Small Interfering RNAs into Chitosan Sponge for Bone Tissue Engineering.

Highly efficient healing of critical sized articular cartilage defect in situ using a chemically nucleoside-modified mRNA-enhanced cell therapy

Resveratrol-Loaded Poly(d,l-Lactide-Co-Glycolide) Microspheres Integrated in a Hyaluronic Acid Injectable Hydrogel for Cartilage Regeneration

Novel Synthesized Nanofibrous Scaffold Efficiently Delivered hBMP-2 Encoded in Adenoviral Vector to Promote Bone Regeneration

Injectable and Photocurable Gene Scaffold Facilitates Efficient Repair of Spinal Cord Injury

Cell-free 3D scaffold with two-stage delivery of miRNA-26a to regenerate critical-sized bone defects

Co‐Polymer Carrier with Dual Advantages of Cartilage‐Penetrating and Targeting Improves Delivery and Efficacy of microRNA Treatment of Osteoarthritis

A doxorubicin and siRNA coloaded nanolamellar hydroxyapatite/PLGA electrospun scaffold as a safe antitumor drug delivery system

In Situ Deposition of Drug and Gene Nanoparticles on a Patterned Supramolecular Hydrogel to Construct a Directionally Osteochondral Plug

Designing biomaterials for the delivery of RNA therapeutics to stimulate bone healing

A novel therapeutic strategy for cartilage diseases based on lipid nanoparticle-RNAi delivery system

Nanoparticle Functionalization with Genetically-Engineered Mesenchymal Stem Cell Membrane for Targeted Drug Delivery and Enhanced Cartilage Protection

Bone tissue engineering based on sustained release of MiR29c-modified framework nucleic acids from an injectable hydrogel

Programmed Biomolecule Delivery Orchestrate Bone Tissue Regeneration Via MSC Recruitment and Epigenetic Modulation

In Situ Osteochondral Regeneration by Controlled Release of Stromal Cell-Derived Factor-1 Chemokine from Injectable Biomaterials: A Preclinical Evaluation in Animal Model

Chitosan-Based Hydrogels Embedded with Hyaluronic Acid Complex Nanoparticles for Controlled Delivery of Bone Morphogenetic Protein-2

Bioswitchable Delivery of microRNA by Framework Nucleic Acids: Application to Bone Regeneration

DNA‐Grafted Hyaluronic Acid System with Enhanced Injectability and Biostability for Photo‐Controlled Osteoarthritis Gene Therapy

Cartilage lacuna-biomimetic hydrogel microspheres endowed with integrated biological signal boost endogenous articular cartilage regeneration